The COVID-19 pandemic starkly highlighted vulnerabilities within the global pharmaceutical supply chain, particularly regarding active pharmaceutical ingredients (APIs), the vital components of modern medicines. As the crisis unfolded, Europe faced acute shortages of essential drugs and APIs, exposing the continent’s heavy reliance on imports, especially from Asia. This situation prompted a significant reevaluation among industry leaders, governments, and policymakers across Europe. A transformative shift is now underway, focusing on reshoring production efforts and striving for enhanced API independence. This article delves into these trends, the strategic motivations behind them, and Europe’s evolving role in the global pharmaceutical landscape.
The Historical Context of API Dependence in Europe
For decades, the economic impetus to minimise costs led pharmaceutical companies to offshore API production to countries like India and China. By 2019, a staggering 70% of global API production capacity was concentrated in Asia, with China alone accounting for nearly half. European manufacturers faced escalating costs alongside stringent environmental and safety regulations, ultimately resulting in a dramatic reduction in the number of domestic API manufacturing sites, plummeting from over 2,000 in the 1990s to fewer than 600 projected for 2024.
The implications of this outsourcing were starkly illustrated during the early waves of COVID-19, when export restrictions, border closures, and surging demand combined to create critical shortages of medications such as analgesics and antibiotics. Data from the European Medicines Agency (EMA) revealed that more than 90 medicinal products suffered acute supply shortages during 2020 and 2021.
Policy and Market Drivers of Reshoring
The push towards reshoring—relocating manufacturing back to domestic markets—has become a focal point in Europe’s strategy for pharmaceutical resilience. Initiatives like the 2022 pharmaceutical strategy set forth by the European Commission, combined with national programs such as France’s €1.5 billion health sovereignty effort and Germany’s €1.2 billion resilience fund, demonstrate a concerted effort to reinvigorate local API production. By mid-2025, at least 18 EU member states are expected to launch public-private partnerships aimed at bolstering domestic API manufacturing.
However, while policies are vital, market dynamics also play a crucial role. The global contract development and manufacturing organisation (CDMO) sector, where Europe is an important player, is projected to grow at a compound annual growth rate (CAGR) of 11.5% in the coming years. Increased adoption of digital manufacturing technologies and green chemistry approaches among European API sites aims to enhance quality and sustainability, allowing them to compete effectively with cheaper alternatives from Asia.
A poignant example of this shift is Sanofi’s recent investment in its Vertolaye plant, which will focus on producing major antibiotics and painkillers using advanced process automation to achieve energy efficiency and cost reduction.
A Strategic Shift in Sourcing Practices
Prior to the pandemic, pharmaceutical supply chains prioritised lean inventory and global sourcing, strategies that ultimately jeopardised resilience. The unfolding crisis has shifted focus towards “just in case” sourcing strategies, which involve larger stockpiling efforts, increased regionalisation, and dual sourcing arrangements to mitigate risks.
Moreover, European regulators now mandate that companies map their API supply chains to identify weak links and high-risk dependencies. This move towards enhanced transparency, led by the EMA and national agencies, supports quicker responses to shortages and targeted investments in domestic production capabilities.
Efforts to enhance environmental sustainability are gaining traction too. With the anticipated introduction of stringent green API standards by 2027, adherence to these regulations is likely to raise production costs by at least 8%. However, this investment in sustainability is viewed as essential for long-term resilience and consumer trust.
Future Prospects: Opportunities and Challenges
According to recent estimates, the European API market is poised for growth, expected to reach $21.7 billion by 2024, with continued expansion forecasted up to 2032 at a CAGR of 7.3%. Increased capacities in key categories such as antibiotics and biologics reflect this optimistic outlook. Nonetheless, challenges persist, including maintaining cost competitiveness against Asian suppliers, the need for skilled labour, and navigating complex regulatory landscapes. Despite these hurdles, there’s a consensus that Europe’s focus on sustainable practices and innovation can position it as a leader in API production.
The journey towards greater self-sufficiency in API manufacturing is ongoing, underscoring both the urgency and complexity of achieving a resilient pharmaceutical supply chain. The reshoring initiatives, propelled by pandemic lessons and geopolitical realities, have catalysed unprecedented investments. As we advance towards 2032, Europe is not only poised to redefine its pharmaceutical landscape but also to influence global norms regarding resilience and operational transparency.
In conclusion, Europe’s transformation from dependency to self-sufficiency in API manufacturing, albeit still a work in progress, signals a pivotal shift in the industry’s dynamics. The interplay of robust policy frameworks, commitment to innovation, and a focus on sustainability is expected to solidify Europe’s role as a critical player in the global pharmaceutical supply chain.
Reference Map
- Lead article on API sourcing and the supply chain
- Xellia Pharmaceuticals and challenges of sustaining manufacturing in Europe
- Crisis in the market for essential generic medicines
- Western companies exploring alternatives due to geopolitical legislation
- U.S. pharmaceutical industry dynamics amid tariff considerations
- U.S. drug supply chain issues and legislative responses
- Effects of the Ukraine crisis on European pharmaceutical manufacturing
Source: Noah Wire Services
Subscribe to Industry Updates
